Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YV4F
|
||||
| Former ID |
DCL000581
|
||||
| Drug Name |
Ocrelizumab
|
||||
| Synonyms |
Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Relapsing or primary progressive forms of multiple sclerosis [ICD10:G35] | Approved | [1] | ||
| Company |
Genentech
|
||||
| CAS Number |
CAS 637334-45-3
|
||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [2], [3] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Drugs@FDA (Edaravone) | ||||
| REF 2 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | ||||
| REF 3 | Clinical pipeline report, company report or official report of Roche (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.